What is the Historic and Current Scenario of the Cancer Profiling Market?
The cancer profiling market has seen considerable growth due to a variety of factors.
• The size of the cancer profiling market has seen expedited expansion in the past few years. The projection is for an increase from $13.48 billion in 2024 to a whopping $15.05 billion in 2025, presenting a compound annual growth rate (CAGR) of 11.6%. This growth throughout the historical period can be traced back to the rising rates of cancer occurrences, the upsurge in precision medicine methodologies, the endorsement of biomarkers in clinical settings, advancements in drug development and targeted therapies, along with enhanced awareness and patient advocacy.
What Can Be Expected from the Cancer Profiling Market?
The Cancer Profiling market is expected to maintain its strong growth trajectory in upcoming years.
• The size of the cancer profiling market is projected to expand significantly in the coming years. The market is expected to reach $23.08 billion by 2029, growing at a compound annual growth rate (CAGR) of 11.3%.
The projected growth can be linked to several factors including the adoption of artificial intelligence, worldwide research collaborations, growing applications of liquid biopsy, regulatory backing for precision medicine, and a heightened focus on early detection. Key trends predicted for the forecast period encompass the supremacy of liquid biopsy, extensive genomic profiling, the emergence of immunoprofiling, the establishment of cooperative data sharing networks, and single-cell sequencing.
What Are the Critical Driver Fuelling The Cancer Profiling Market's Growth?
The expected surge in the number of cancer cases is anticipated to trigger expansion in the cancer profiling market. The mention of cancer incidence refers to the record of fresh cancer cases within a specific demographic in a set period. This increase in cancer cases is brought about by factors such as urbanization, an enlarging aging populace, shifts in lifestyles, environmental factors, and genetic predispositions. Profiling of cancer assists in distinguishing particular molecular or genetic alterations in a tumor, like gene mutations or other modifications in tumor DNA, which is instrumental in the cycle of cancer treatment. For example, the American Cancer Society, a voluntary organization based in the US, projected in 2022 that the number of fresh cancer cases and fatalities would reach 1.9 million diagnoses and 609,360 cancer deaths in the United States. Consequently, this surge in cancer cases stimulates expansion in the cancer profiling market.
How Is The Cancer Profiling Market segmented?
The cancer profiling market covered in this report is segmented –
1) By Technology: Immunoassays, PCR (Polymerized Chain Reaction), NGS (Next-Generation Sequencing), Microarrays, In-Situ Hybridization
2) By Biomarker Type: Genomic Biomarkers, Protein Biomarkers
3) By Cancer Type: Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Melanoma Cancer, Other Cancers
4) By Application: Research Applications, Clinical Applications, Screening, Diagnostics, Prognostics, Other Applications
Subsegments:
1) By Immunoassays: Enzyme-Linked Immunosorbent Assay (ELISA), Western Blotting, Luminex xMAP Technology, Radioimmunoassays
2) By PCR (Polymerase Chain Reaction): Quantitative PCR (qPCR), Digital PCR (dPCR), Reverse Transcription PCR (RT-PCR)
3) By NGS (Next-Generation Sequencing): Whole Genome Sequencing (WGS), Whole Exome Sequencing (WES), Targeted Sequencing, RNA Sequencing (RNA-Seq)
4) By Microarrays: DNA Microarrays, RNA Microarrays, SNP Arrays
5) By In-Situ Hybridization: Fluorescence In-Situ Hybridization (FISH), Chromogenic In-Situ Hybridization (CISH)
Pre-Book The Cancer Profiling Global Market Report 2025 Report For Swift Delivery And Comprehensive Insights:
What New Trends Are Influencing The Cancer Profiling Market?
Prominent firms in the cancer profiling market concentrate on creating innovative broad coverage solutions. This method involves examining 517 cancer-related genes in nearly 30 different kinds of solid tumors. It marks an extensive study of an array of genetic mutations, biomarkers, and molecular targets. As an example, Illumina, Inc., a biotechnology company from the U.S., introduced the TruSight Oncology Comprehensive (TSO) test in March 2022, making it a notable progress in cancer diagnostics. Constituting a new in vitro diagnostic test in Europe that profiles cancer mutations, it paves the way for patient specific targeted therapies. The test covers close to 30 solid tumor types and 517 genes while analyzing both DNA and RNA. Turning in results within four to five days, this speedy test also carries a CE mark complying with European quality standards, thereby eliminating the necessity for multiple gene assays on varying tissue samples.
Who Are the Key Players In The Cancer Profiling Market?
Major companies operating in the cancer profiling market include:
• Illumina Inc.
• Qiagen NV
• NeoGenomics Inc.
• Sysmex Corporation
• HTG Molecular Diagnostics Inc.
• Caris Life Sciences
• NanoString Technologies Inc.
• Guardant Health Inc.
• Foundation Medicine Inc.
• Roche Diagnostics Corporation
• F. Hoffmann-La Roche Ltd.
• Thermo Fisher Scientific Inc.
• Genscript Biotech Corporation
• Tempus Labs Inc.
• Hologic Inc.
• Predictive Oncology Inc.
• Abbott Laboratories
• Agilent Technologies Inc.
• PerkinElmer Inc.
• Siemens Healthineers
• Genomic Health Inc.
• Natera Inc.
• ArcherDX Inc.
• Personal Genome Diagnostics Inc.
• Enzo Biochem Inc.
• Cancer Genetics Inc.
• OncoDNA SA
• Ribomed Biotechnologies Inc.
• Biocartis Group NV
• N-of-One Inc.
• Cynvenio Biosystems Inc.
• Inivata Ltd.
• Burning Rock Biotech Limited
• PathAI Inc.
• GENEWIZ Inc.
• Genoptix Inc.
• Oncomine Dx Target Test
• OmniSeq Comprehensive
• Resolution Bioscience
• OncoCyte Corporation
What Is The Most Dominant Region In The Cancer Profiling Market?
North America was the largest region in the cancer profiling market in 2024. The regions covered in the cancer profiling market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
